Atul Grover, MD, PhD, executive director of the AAMC Research and Action Institute, participated as an expert panelist at the 42nd annual JP Morgan Healthcare Conference in San Francisco, California. The conference is the largest health care investment symposium in the industry, bringing together more than 8,000 senior government officials, investors, and industry professionals, and 550 global health care companies to discuss the latest market trends and medical innovations.
Grover joined featured panelists Dora Hughes, MD, MPH, CMO, Centers for Medicare and Medicaid Services, and Susan Van Meter, MA, CEO, American Clinical Lab Association, with moderation by Ipsita Smolinski, MPH, MBA, founder and managing director, Capitol Street, and Rachel Vatnsdal, JP Morgan.
The panel discussion, entitled “Diagnostic Testing: Pathways, Policies and Payment in a New Year," focused on current and pending health care reform policies in diagnostic medicine, including the implications of the latest federal regulations of laboratory developed testing (LTDs). Grover emphasized the role of academic health systems in discovery and innovation across the life cycle of therapeutics and diagnostics. He noted that the proposed policy to enforce regulation of LTDs as medical devices as proposed under current law would have a detrimental effect on the ability of academic medical centers to conduct innovative medical research and to provide specialized and patient-centric medical care.
Grover was pleased to contribute to the conversation, which spanned a variety of health care topics that the AAMC Research and Action Institute covers in publications ranging from test development to value-based care, as well as the difference between health care prices and costs.